Citations

Clear

949 citation(s) found for "Li, Bryan".

Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast Cancer
Huang, Chen , Srinivasan, Ramakrishnan Rajaram , Lewis, Alaina , Sallas, Christina , Zhao, Na , Cao, Jin , Pilcher, Jacob B., Moon, Chang In, Liao, Yuxing , Rimawi, Mothaffar F. , Malovannaya, Anna , Li, Shunqiang , Kraushaar, Daniel C. , Goetz, Matthew P., Boughey, JC , Wang, Liewei, Kalari, Krishna R., Suman, Vera J., Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, F, Welm, Bryan E. , Welm, Alana L. , Zhang, Bing , Lei, Jonathan T , Zhao, Na , Wen, Bo , Rimawi, Mothaffar , Lei, Jonathan T. , Dobrolecki, Lacey E. , Vasaikar, Suhas , Landua, John David , Pilcher, Jacob B. , Hilsenbeck, Susan Galloway , Ellis, Matthew J. , Petrosyan, Varduhi, Li, Kai shang , Saltzman, Alexander B. , Jain, Antrix , Wulf, Gerburg M. , Marangoni, Elisabetta , Wang, Tao , Goetz, Matthew P. , Damodaran, Senthil , Zheng, Xiaofeng , Meric‐Bernstam, Funda , Echeverria, Gloria Vittone , Anurag, Meenakshi , Chen, Xi , Lewis, Michael T.

Mayo Clinic

No container title available | December 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.12.09.627518 | PMID 39713418 Get It

Abstract Chemotherapy regimens for triple-negative breast cancer (TNBC) combine agents without knowing which agents drive response. Consequently, predictors derived from multi-agent regimens cannot be assumed to generalize to individual drugs or other regimens, motivating development of treatment-matched predictors. Here, we used TNBC patient-derived xenografts (PDXs) treated with carboplatin, docetaxel, or the combination to deconvolute drug-specific responses and identify associated molecular features. Combination treatment rarely improved upon the best single agent, with enhanced responses in only 13% of PDXs and antagonism in a comparable fraction. Proteogenomic analyses identified high cytokeratin-5 (KRT5) as a general marker of chemotherapy responsiveness and KRT5 immunohistochemistry discriminated responsive PDXs (AUROC, 0.83). To train treatment-specific predictors, we integrated these data with independent PDX and clinical cohorts with responses assessed after anthracycline-free platinum, taxane, or platinum-taxane therapy, ensuring response corresponded to the modeled treatment. Four feature selection strategies yielded largely nonoverlapping biomarker panels converging on treatment-relevant pathways. On independent test data, RNA-based predictors of complete response (CR) to platinum-based (carboplatin or cisplatin) and taxane-based (docetaxel or paclitaxel) chemotherapy achieved AUROCs of 0.80 and 0.86, respectively. For platinum-taxane regimens (carboplatin plus docetaxel or paclitaxel), proteomic-guided feature selection generated a 10-biomarker, protein- informed RNA predictor of pathologic complete response (pCR) that outperformed RNA-only feature selection and achieved an AUROC of 0.85 in an independent clinical cohort, while retaining practicality as an RNA-based assay. Treatment-matched integration of multi-omic PDX and clinical datasets provides a framework for chemotherapy-specific predictors with clinically relevant performance, supporting biomarker-guided precision selection and treatment optimization for patients with TNBC. Statement of significance Integration of multi-omic data from patient-derived xenografts with treatment-matched clinical cohorts yielded three retrospectively validated predictors of platinum, taxane, and platinum+taxane response, enabling biomarker-guided chemotherapy selection for patients with triple-negative breast cancer.
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda
Valcárcel, Bryan , Savage, Kerry J. , Link, Brian K. , Leonard, John P. , Kelly, Kara M. , Thanarajasingam, Gita , Cerhan, James R. , Pro, Barbara, Gordon, Leo I. , Thompson, Carrie A. , Smith, Sonali M. , Morton, Lindsay M , Cerhan, James R , Link, Brian K , Gordon, Leo I , Savage, Kerry J , Morton, Lindsay M.

Mayo Clinic

JCO Oncology Practice | December 6, 2024 | Volume: 21 | Issue: 6 | Pages: 801-812

10.1200/op.24.00364 | PMID 39642333 Get It

PURPOSE Lymphomas are a heterogeneous group of diseases that develop in individuals of all ages and have variable prognoses. Improved survival resulting from therapy advances has led to the emergence of diverse late effects. Although several (US)–based organizations have developed survivorship guidelines, the distinct features of lymphoma subtypes and diverse therapies used raise concerns regarding their applicability to lymphoma survivors. We compared survivorship recommendations (outside primary disease monitoring) between US clinical guidelines. METHODS We extracted information from 17 guidelines from five US-based organizations: ASCO (n = 11), American Cancer Society (n = 1), Children's Oncology Group (n = 1), Center for International Blood and Marrow Transplant Research (n = 1), and the National Comprehensive Cancer Network (n = 3). Guidelines were evaluated to determine whether they offer recommendations on physical effects , psychosocial and quality of life ( QOL ), and health promotion and prevention . Comparisons were focused on second primary malignancy, cardiovascular complications, and vaccination. RESULTS Survivorship recommendations on physical effects and psychosocial and QOL mainly differ in the timing and approaches for screening. Vaccination recommendations were primarily derived from other cancer populations. Identified research gaps were a lack of understanding of the risk of late effects across lymphoma subtypes, the role of social determinants of health in survivorship, and the lack of a survivorship care model that integrates lymphoma subtypes and treatment exposures. CONCLUSION This study raises awareness about the complexity and challenges of managing survivors under the umbrella diagnosis of lymphoma. The inconsistency and incompleteness of existing guidelines may lead to suboptimal survivorship care. We propose expert-based research priorities to address gaps and unmet needs to help develop risk-based follow-up recommendations to optimize survivorship care for lymphoma survivors.
Incidence and Prevalence of Chronic Lymphocytic Leukemia in the 7-County Region Around Mayo Clinic, Rochester, Minnesota
Vallejo, Bryan Alexis , Achenbach, Sara J., Vachon, Celine M. , Cerhan, James R., Schwager, Susan M., Shanafelt, Tait D. , Hanson, Curtis A. , Call, Timothy G. , Shanafelt, Tait D , Rabe, Kari G. , Norman, Aaron D. , Vachon, Celine M. , Cerhan, James R. , Braggio, Esteban , Parikh, Sameer A. , Kay, Neil E. , Slager, Susan L.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 6801-6801

10.1182/blood-2024-209069 Get It

Background: Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in the United States (US), with an estimated incidence of 20,700 cases in 2024. Population-based studies conducted in Olmsted County (OC), Minnesota, reported an increase in CLL incidence over a 55-year period (1935 through 1989), which was attributed to increased detection of early-stage cases in individuals over age 50. In an updated study from 2000 to 2010 in OC, we reported no further increase in the incidence of CLL using the 2008 International Workshop on CLL (IWCLL 2008) guidelines. Additionally, when we compared the 1996 National Cancer Institute Working Group (NCI-WG 96) criteria with the IWCLL 2008 guidelines incorporating the monoclonal B-cell lymphocytosis designation, we found that the use of the IWCLL 2008 guidelines reduced the overt CLL incidence, modified the distribution of Rai Stages at diagnosis, and shortened the median time to first treatment (TTFT). Over the last two decades, 5-year survival for CLL has increased due to new therapies and improved supportive care. Herein we provide updated data on the incidence, prevalence, and natural progression of CLL in OC and studied similar features in an expanded 6-county region around Mayo Clinic, Rochester. Methods: We utilized the Rochester Epidemiology Project (REP), a population-based medical records linkage system, to identify CLL cases from 2000 to 2020 using International Classification of Diseases codes. We included individuals residing in OC and the expanded 7-county region (REP-7, including OC), for which data became available starting in 2010. CLL cases were included if they met the IWCLL 2008 criteria. All CLL diagnoses were confirmed by manual review of medical records and data on CLL-related factors were collected, including treatment status, prior history of other cancers, and overall survival (OS). Age- and sex-specific incidence rates were derived from REP census data and adjusted to the 2020 US white population. OS analyses were conducted using the Kaplan-Meier method. TTFT was calculated with death as a competing risk. Cox regression was used to evaluate the effect of decade on TTFT and OS among patients in OC. Results: From 2010-2020, 242 patients were diagnosed with CLL in REP-7, and between 2000-2020, 174 patients were diagnosed in OC. Among the 242 CLL patients in REP-7, the median age at diagnosis was 71 years (range 30-96),158 (65%) were male, 236 (99%) were white, and 74 (31%) had a history of other cancer, with non-melanoma skin cancer being the most common. After age and sex adjustment to the 2020 US white population, the CLL incidence in REP-7 and OC from 2010 to 2020 was 7.8 and 8.1 per 100,000 individuals, respectively. In OC, the age- and sex-adjusted CLL incidence from 2000 to 2020 was 7.5 per 100,000 individuals, showing no significant trend changes over time. Among the 242 patients diagnosed with CLL in REP-7 between 2010 and 2020, 102 received treatment with a median TTFT of 9.8 years. In OC from 2000 to 2020, 79 out of 174 patients received treatment with a median TTFT of 9.4 years. When comparing across two decades in OC, the median TTFT was 12.8 years for the period from 2000 to 2009, decreasing to 5.9 years between 2010 and 2020, but was not significantly different after accounting for age and sex. The median OS for patients diagnosed with CLL in REP-7 from 2010 to 2020 was 11 years. The median OS for patients in OC between 2000 to 2020 was 12.6 years. When comparing across decades in OC, the median OS was 8.9 years for the period from 2000 to 2009, increasing to 13.6 years for those diagnosed between 2010 and 2020, but this trend was not significantly different after accounting for age and sex. Prevalence data for REP-7 and OC were analyzed as of 01/01/2020. Additionally, prevalence data for OC were available for 01/01/2010. In REP-7, the prevalence of CLL was 97 per 100,000 individuals on 01/01/2020. In OC, the CLL prevalence was 86 per 100,000 individuals on 01/01/2010, and 100 per 100,000 individuals on 01/01/2020. Conclusions: We observed no substantial increase in the incidence rates of CLL in REP-7 from 2010 to 2020, nor in the 20 years of available data from OC. However, the prevalence of CLL in OC increased by 16% from 2010 to 2020. Additionally, evidence indicated a longer OS among newly diagnosed CLL cases in OC compared to previous decades, suggesting a potential impact of improved therapeutic approaches on OS.
Principles of Stereotactic Surgery
Jensen, Michael A. , Neimat, Joseph S. , Kerezoudis, Panagiotis , Ali, Rushna , Halpern, Casey H. , Ojemann, Steven , Ponce, Francisco A. , Lee, Kendall H. , Haugen, Laura M., Permezel, Fiona , Klassen, Bryan T. , Miller, Kai J. , Permezel, Fiona E , Klassen, Bryan T , Kondziolka, Douglas , Miller, Kai J , Ali, Rushna , Jensen, Michael A , Richardson, Robert Mark , Kondziolka, Douglas

Mayo Clinic

Operative Neurosurgery | December 3, 2024 | Volume: 28 | Issue: 3 | Pages: 303-321

10.1227/ons.0000000000001422 | PMID 39627171 Get It

BACKGROUND AND OBJECTIVES: Stereotactic procedures are used to manage a diverse set of patients across a variety of clinical contexts. The stereotactic devices and software used in these procedures vary between surgeons, but the fundamental principles that constitute safe and accurate execution do not. The aim of this work is to describe these principles to equip readers with a generalizable knowledge base to execute and understand stereotactic procedures. METHODS: A combination of a review of the literature and empirical experience from several experienced surgeons led to the creation of this work. Thus, this work is descriptive and qualitative by nature, and the literature is used to support instead of generate the ideas of this framework. RESULTS: The principles detailed in this work are categorized based on 5 clinical domains: imaging, registration, mechanical accuracy, target planning and adjustment, and trajectory planning and adjustment. Illustrations and tables are used throughout to convey the concepts in an efficient manner. CONCLUSION: Stereotactic procedures are complex, requiring a thorough understanding of each step of the workflow. The concepts described in this work enable functional neurosurgeons with the fundamental knowledge necessary to provide optimal patient care.
A General Framework for Characterizing Inaccuracy in Stereotactic Systems
Jensen, Michael A. , Neimat, Joseph S. , Kerezoudis, Panagiotis , Ali, Rushna , Halpern, Casey H. , Ojemann, Steven , Ponce, Francisco A. , Lee, Kendall H. , Haugen, Laura M., Klassen, Bryan T. , Miller, Kai J. , Kondziolka, Douglas , Miller, Kai J , Ali, Rushna , Jensen, Michael A , Richardson, Robert Mark , Kondziolka, Douglas

Mayo Clinic

Operative Neurosurgery | December 3, 2024 | Volume: 28 | Issue: 3 | Pages: 322-336

10.1227/ons.0000000000001423 | PMID 39627169 Get It

BACKGROUND AND OBJECTIVES: Identifying and characterizing sources of targeting error in stereotactic procedures is essential to maximizing accuracy, potentially improving surgical outcomes. We aim to describe a generic framework which characterizes sources of stereotactic inaccuracy. METHODS: We assembled a list of stereotactic systems: ROSA, Neuromate, Mazor Renaissance, ExcelsiusGPS, Cirq, STarFix (FHC), Nexframe, ClearPoint, CRW, and Leksell. We searched the literature for qualitative and quantitative work identifying and quantifying potential sources of inaccuracy and describing each system's implementation using Standards for Reporting Qualitative Research guidelines. Our literature search spanned 1969 to 2024, and various studies were included, with formats ranging from phantom studies to systematic reviews. Keyword searches were conducted, and the details about each system were used to create a framework for identifying and describing the unique targeting error profile of each system. RESULTS: We describe and illustrate the details of various sources of stereotactic inaccuracies and generate a framework to unify these sources into a single framework. This framework entails 5 domains: imaging, registration, mechanical accuracy, target planning and adjustment, and trajectory planning and adjustment. This framework was applied to 10 stereotactic systems. CONCLUSION: This framework provides a rubric to analyze the sources of error for any stereotactic system. Illustrations allow the reader to understand sources of error conceptually so that they may apply them to their practice.
American College of Surgeons Cancer Program Annual Report from 2021 Participant User File
Day, Courtney N. , Palis, Bryan E., Plichta, Jennifer K, Wasif, Nabil , Plichta, Jennifer K. , Plichta, Jennifer K , Habermann, Elizabeth B. , Weigel, Ronald J. , Boughey, Judy C.

Mayo Clinic

Journal of the American College of Surgeons | December 3, 2024 | Volume: 240 | Issue: 1 | Pages: 95-110

10.1097/xcs.0000000000001214 | PMID 39625171 Get It

The National Cancer Database (NCDB) collects data from approximately 1,500 Commission on Cancer (CoC) facilities and represent 73.7% of newly diagnosed cancers nationwide. The American College of Surgeons Cancer Program developed it first annual report from the NCDB 2021 participant user file reporting new observations and recent trends of cancer diagnoses, patient demographics, and treatments as well as an in-depth report on treatment and outcomes in breast, pancreas, and colon cancers. Of the 1,328,131 cancers diagnosed in 2021 at 1,281 reporting CoC hospitals, one-fifth continue to be female breast cancer. In 2021, the NCDB’s 5 most common adult cancers were breast, prostate, lung, colon, and melanoma and varied by patient sex. Use of neoadjuvant systemic therapy increased in recent years in pancreas, breast, and urinary bladder cancer, although a slight decrease in pancreas and breast cancer was observed in 2021. Breast cancer has high survival rates, especially in lower-stage disease and estrogen receptor-positive/human epidermal growth factor receptor 2-negative disease. There is increase in neoadjuvant systemic therapy use, especially in human epidermal growth factor receptor 2-positive disease and estrogen receptor-negative disease. Colon cancer presents most commonly as stage III or II with a primary in the cecum or ascending colon in 38.9%. The majority are microsatellite instability stable, Kirsten rat sarcoma viral oncogene homologue normal, and CEA positive. Survival is most dependent on stage but also associated with microsatellite instability stability, abnormal Kirsten rat sarcoma viral oncogene homologue, and positive CEA. Pancreatic cancer presents with stage IV disease in nearly half, although an increase in stage I disease is seen. The most common location is pancreatic head. Survival is relatively low and most dependent on stage.
Spectral changes in motor thalamus field potentials during movement
Klassen, Bryan T. , Baker, Matthew , Jensen, Michael A. , Valencia, Gabriela Ojeda , Miller, Kai J. , Baker, Matthew R , Ojeda Valencia, Gabriela , Klassen, Bryan T , Jensen, Michael A

Mayo Clinic

Journal of Neurophysiology | November 26, 2024 | Volume: 133 | Issue: 1 | Pages: 101-108

10.1152/jn.00419.2024 | PMID 39589825 Get It

We studied movement-associated spectral changes in human motor thalamus and observed focal increases in broadband power with movement. This biomarker may be used as a tool for intraoperative functional mapping, DBS targeting, and closed-loop device control.
Clinical Evaluation of the NaviNetics Stereotactic System Using Intraoperative Portable Surgical Imaging System in DBS Surgery
Shin, Jee Won , Mandybur, Ian, Hussein, S.H., Klassen, Bryan T. , Gregg, Nick, Miller, Kai J. , Shin, Hojin , Vansickle, David, Lee, Kendall H. , Scheitler, Kristen M. , Sharaf, Basel , Mandybur, Ian, Grewal, Sanjeet S. , Chang, Jin Woo , Oh, Yoonbae

Mayo Clinic

Operative Neurosurgery | November 18, 2024 | Volume: 29 | Issue: 1 | Pages: 93-101

10.1227/ons.0000000000001427 | PMID 39883866 Get It

BACKGROUND AND OBJECTIVES: A typical workflow for deep brain stimulation (DBS) surgery consists of head frame placement, followed by stereotactic computed tomography (CT) or MRI before surgical implantation of the hardware. At some institutions, this workflow is prolonged when the imaging scanner is located far away from the operating room, thereby increasing workflow times by the addition of transport times. Recently, the intraoperative O-arm has been shown to provide accurate image fusion with preoperative CT or MR imaging, suggesting the possibility of obtaining an intraoperative localization scan and postoperative confirmation. In this article, we aim to evaluate the compatibility of the stereotactic frame system with the intraoperative O-arm system regarding lead accuracy and surgical flow. METHODS: A total of 17 patients undergoing DBS surgery for movement disorders were evaluated. One patient underwent both the stereotactic CT and O-arm localization, while 16 patients underwent only intraoperative O-arm localization. Following lead placement, intraoperative O-arm imaging was obtained to evaluate the accuracy of the lead placement. Accuracy was defined as the error measured as the distance from the center of the planned trajectory to the cannula. RESULTS: Less than 0.1 mm difference was found between the O-arm imaging technique and CT image localization of the NaviNetics stereotactic head frame in DBS surgery. Of the 16 patients who underwent the intraoperative O-arm imaging alone, the targets included bilateral ventral intermediate nucleus (16 leads), bilateral globus pallidus internus (4 leads), and subthalamic nucleus (12 leads). The mean ± SD radial error in the probe's eye view was 0.71 ± 0.33 mm for n = 32 leads. No tract hemorrhage was observed. CONCLUSION: Intraoperative O-arm imaging can be used safely and effectively for stereotactic registration and lead placement confirmation with the stereotactic system in both awake and asleep DBS surgery.
Is minimally invasive glaucoma surgery killing trabeculectomies?
Loon, Seng Chee, White, Andrew , Ang, Bryan C H

Mayo Clinic

Current Opinion in Ophthalmology | November 15, 2024 | Volume: 36 | Issue: 2 | Pages: 146-151

10.1097/icu.0000000000001108 | PMID 39774269 Get It

Purpose of review The introduction of minimally invasive glaucoma surgery (MIGS) has changed the surgical landscape of glaucoma surgery. For more than four decades, the most commonly performed glaucoma surgery around the world has been the trabeculectomy. This article examines whether trabeculectomy is still the predominant procedure in glaucoma today, in the context of rapidly emerging MIGS devices and procedures. Recent findings There is a growing trend of mild to moderate glaucoma cases undergoing MIGS procedures instead of trabeculectomy. Glaucoma drainage device implantation may also have taken away a significant share of the filtering surgery performed for more severe glaucoma. In addition, the availability and economics of implants has an influence on the prevalence of trabeculectomy. Summary Currently, trabeculectomy surgery is still the most common glaucoma surgery performed around the world. However, the proportion of glaucoma surgeries undergoing MIGS is increasing rapidly.
Abdominal Oblique and Rectus Muscle Injuries in Major and Minor League Baseball Players: An Updated Epidemiological Review
Tenner, Zachary M. , Lamba, Abhinav , Griffith, Timothy B. , Conte, Stan, Camp, Christopher L. , Lamba, Abhinav , Griffith, Timothy Bryan

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 15, 2024 | Volume: 12 | Issue: 11 | Pages: No page available

10.1177/23259671241293454 | PMID 39555318 Get It

Background: Abdominal musculature injuries comprise the third most prevalent time-loss injury across professional baseball. Despite increased awareness and prevention attempts in the recent decade, the trends of these abdominal injury numbers in Major League Baseball (MLB) are not fully understood. Purposes: To update the trends in oblique and intercostal injuries, analyze the impact of these injuries based on time out of play, and identify factors that correlate with increased injury severity to help with recovery time prognostication for the sports medicine community. Study Design: Descriptive epidemiology study. Methods: Using the MLB Health and Injury Tracking System, the authors identified all abdominal and core musculature injuries that resulted in time out of play in MLB and Minor League Baseball (MiLB) between the 2011 and 2021 seasons. These were filtered for injuries that resulted in ≥1 days missed (DM) during spring training, the regular season, and postseason. A Student t test was utilized to assess for significant differences for all normally distributed values. Regression analysis was utilized for determining change over time. For all statistical comparisons, the threshold for alpha was set to P < .05. Results: During the study period between 2011 and 2021, there were 4560 total abdominal injuries among 3401 athletes. When filtered for in-season, time-loss injuries defined as spring training, regular season, and postseason, there were 2890 injuries. Of these, 1928 were oblique injuries, 453 were intercostal injuries, and 115 were rectus injuries. The number of oblique injuries each season increased for all of baseball ( P < .001), as well as for MLB ( P = .009) and MiLB ( P = .012) individually. Of the 1928 oblique injuries, 498 (26%) oblique injuries occurred at the MLB level and 1430 (74%) occurred at the MiLB level. Batting and pitching-related injuries comprised 860 (45%) and 729 (38%) oblique injuries, with a total of 18,455 DM and 20,891 DM, respectively. This corresponded to a mean of 22 DM for batting injuries and 29 DM for pitching injuries (mean difference, 7.2; 95% CI, 5.27-9.13; P < .001). Conclusion: This decade-long study on professional baseball revealed a significant increase in abdominal oblique injuries across MLB and MiLB, with the largest number of injuries observed in the 2021 season. Meanwhile, there was a significant decrease in intercostal injuries across professional baseball during these years. Such injuries continue to pose challenges, leading to substantial DM per injury and affecting players from various positions.